November 10, 2003
Flamel Technologies announces results of meeting of shareholders.

November 6, 2003
Flamel Technologies announces receipt of $20 million from Bristol-Myers-Squibb

October 30, 2003
Flamel Technologies announces third quarter results, partnership with Bristol-Myers-Squibb and improved balance sheet

October 20, 2003
Flamel Technologies announces clearance of antitrust requirement for Basulin licensing deal with Bristol-Myers-Squibb

October 20, 2003
Flamel Technologies announces termination of license agreement with GlaxoSmithKline for sachet formulation of Augmentin

October 9, 2003
Flamel Technologies announces successful closing of ADS offering

October 3, 2003
Flamel Technologies announces pricing of ADS offering

September 24, 2003
Flamel Technologies announces proposed public offering of 3.8 million shares of common stock

August 27, 2003
Bristol-Myers Squibb and Flamel Technologies announce licensing agreement for Basulin®

August 4, 2003
Flamel Technologies announces results of special meeting of shareholders

July 30, 2003
Flamel Technologies announces second quarter results, achievement of two additional milestones from partners due to operating success

June 19, 2003
Flamel Technologies announces election of new members of the board of directors; results of annual meeting

May 8, 2003
Flamel Technologies announces new nominees for the board of directors

April 30, 2003
Flamel Technologies announces first quarter results, showing maintained level of cash and loss per share of $0.10.

April 9, 2003
Biovail acquires rights to controlled release acyclovir -- Genvir -- from Flamel Technologies

March 28, 2003
GlaxoSmithKline and Flamel Technologies announce license agreement

March 24, 2003
Human studies show Flamel Technologies' Medusa protein delivery system BASULIN challenges Lantus for the 24-hour controlled release of insulin

March 18, 2003
Flamel Technologies announces fourth quarter and year-end results; 2002 results show profit of $0.18 per diluted share and improved cash position